In Vitro: FtsZ-IN-7 (compound B8) inhibits the tested Gram-positive bacteria including methicillin-resistant S. aureus (MRSA) (MIC=0.049 μg/mL), B. subtilis (MIC=0.024 μg/mL) and S. pneumoniae (MIC=0.049 μg/mL). FtsZ-IN-7 (1-4× MIC; 0-24 h) inhibits bacterial grwoth. And FtsZ-IN-7 (4× MIC; 4 h) disturbs the cell surface of MRSA ATCC43300, with notable wrinkling and filamentation on their surfaces. FtsZ-IN-7 (4 μg/mL; 10 min; 25 ℃) promotes FtsZ polymerization and (0.02-0.64 μg/mL; 30 min) inhibits the GTPase activity of FtsZ dose-dependently. FtsZ-IN-7 (12.5 μg/mL; 1 h; 37 ℃) revealing the negligible hemolytic activity against human erythrocytes RAW264.7 cells.